Dosing & Uses
Melanoma
Pending FDA for advanced melanoma in patients who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy
Next:
Pharmacology
Mechanism of Action
Preparation of autologous tumor infiltrating lymphocytes (TILs) selected based on antigen specificity and tumor reactivity
Upon reintroduction of lifileucel into the patient, the TILs reinfiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
